研究单位：[1]Eli Lilly and Company[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650032[3]Arizona Arthritis & Rheumatology Associates,P. C. Mesa,Arizona,United States,85202[4]Sun Valley Arthritis Center,LTD Peoria,Arizona,United States,85381[5]Arizona Research Center Phoenix,Arizona,United States,85053[6]University of Arizona Tucson,Arizona,United States,85724[7]Valley Endocrine,Fresno Fresno,California,United States,93720[8]Allergy and Rheumatology Medical Clinic Inc La Jolla,California,United States,92037[9]Desert Medical Advances Palm Desert,California,United States,92260[10]Stanford University Hospital Palo Alto,California,United States,94304
研究目的：
The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study.
The study provides 7 years of additional treatment with baricitinib.
